Actively Recruiting
Pilot Prospective Study of Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer
Led by Mayo Clinic · Updated on 2026-04-22
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating whether images taken using a photon counting detector CT scanner (PCD-CT) can detect the growth of rectal cancer as well as, or better than, MRI scans. The study focuses on patients with rectal cancer and aims to assess how well this newer CT technology can manage the disease compared to the current standard imaging method. Participants will undergo a contrast-enhanced pelvic PCD-CT scan, which is the main procedure being studied. This observational study involves patients who are already clinically referred for staging pelvic MRI and contrast-enhanced CT of the abdomen and pelvis. The study does not involve treatment but focuses on imaging to assist in cancer staging. During the study, participants will have the PCD-CT scan performed, and researchers will evaluate its ability to determine circumferential resection margin (CRM) involvement after the scan. This will help understand if PCD-CT is non-inferior to MRI in assessing rectal cancer growth. The study includes safety monitoring like pregnancy testing for women of childbearing potential and excludes participants with certain medical conditions. The trial runs until the end of 2026, with participant involvement focused on imaging and related assessments.
CONDITIONS
Brief Title
Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients 18 to 99 years of age
- Proven rectal cancer and referred for staging pelvic MRI and contrast-enhanced CT of the abdomen and pelvis
- Tumor size 2 cm or larger as confirmed by endoscopy or imaging report
- Able and willing to sign the informed consent
- Negative pregnancy test for females of child-bearing potential
You will not qualify if you...
- Under 18 years of age
- Unable to provide written informed consent
- Pregnancy
- Estimated Glomerular Filtration Rate (eGFR) of 60 or less
- History of moderate or severe allergic reaction to contrast
- Prior premedication before iodinated contrast
- Bilateral hip replacement or prosthesis
- Consent given but do not undergo clinically indicated MRI for any reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single timepoint
Participants undergo a contrast-enhanced photon-counting detector CT (PCD-CT) scan for local staging of rectal cancer.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
B
Boleyn Andrist
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here